<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Fujirebio Europe 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=44583></link><description><![CDATA[Fujirebio Europe 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 02 May 2026 17:07:06 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2023/12/12_1028147215_20231201094037_4252564946.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Fujirebio and Sysmex Expand CDMO Partnership into the Field of Neurodegenerative Diseases under Their Immunoassay Collaboration]]></title><link>https://www.newswire.co.kr/newsRead.php?no=980016</link><description><![CDATA[TOKYO & KOBE, Japan--(Business Wire/Korea Newswire)--Fujirebio Holdings, Inc. (President &amp; CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization (CDMO) partnership for Sysmex's Automated Immunoassay System HISCL™-Series to include the field of neurodegenera...]]></description><pubDate>Fri, 01 Dec 2023 11:50:00 +0900</pubDate></item><item><title><![CDATA[후지레비오와 시스멕스, 면역분석법 협력 통해 신경퇴행성 질환 영역까지 파트너십 확대]]></title><link>https://www.newswire.co.kr/newsRead.php?no=980017</link><description><![CDATA[도쿄 & 고베, 일본--(Business Wire/뉴스와이어)--후지레비오(Fujirebio Holdings, Inc., 사장 및 최고경영자: 이시카와 고키(Goki Ishikawa))와 시스멕스(Sysmex Corporation, 사장: 아사노 카오루(Kaoru Asano))가 오늘 신경퇴행성 질환 영역을 포함시키기 위해 시스멕스의 자동화 면역분석 시스템 HISCL™-시리즈(Automated Immunoassay System HISCL™-Series)에 대한 의약품 위탁생산·개발(CDMO) 파트너십을 확대하는 계...]]></description><pubDate>Fri, 01 Dec 2023 11:50:00 +0900</pubDate></item></channel></rss>